Coagulation factors II, V, VII, and X, prothrombin gene 20210G→A transition, and factor V Leiden in coronary artery disease high factor V clotting activity is an independent risk factor for myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 4, 1999, Pages 1020-1025

  Redondo, M ^b   Watzke, H H ^b   Stucki, B ^b   Sulzer, I ^b   Demarmels Biasiutti, F ^b   Binder, B R ^b   Furlan, M ^b   Lammle B ^b   Wuillemin, Walter A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

Coagulation factor V; Factor V Leiden; Myocardial infarction; Prothrombin gene

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; PROTHROMBIN; THROMBOPLASTIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0032943711     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.4.1020     Document Type: Article

References (36)

1. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation. 1985; 71:699-708.
2. Sherman CT, Litvack F, Grundfest W. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med. 1986;315:913-919.
3. Davies MJ. The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Thromb Res. 1996;82:1-32.
4. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic-function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
5. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA. 1987;258:1183-1186.
6. Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary artery disease. Thromb Haemost. 1996;75:767-771.
7. Stormorken H, Sakariassen KS. Hemostatic risk factors in arterial thrombosis and atherosclerosis: The thrombin-fibrin and platelet-vWF axis. Thromb Res. 1997;88:1-25.
8. Pankov JS, Folsom AR, Province MA, Rao DC, Eckfeldt J, Heiss G, Shahar E, Wu KK. Family history of coronary heart disease and hemostatic variables in middle-aged adults. Thromb Haemost. 1997;77:87-93.
9. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H, Phillipou H, Lane DA, Morrison CE. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1997;97:785-797.
10. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, della Volpe A, Polli E. The PLAT Study. Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb. 1992;12:1063-1070.
11. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marucchi G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70:380-385.
12. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
13. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a U. K. anticoagulant clinic population. Br J Haematol. 1997;98:353-355.
14. Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost. 1997;78: 990-992.
15. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol. 1997;98:907-909.
16. Ferraresi P, Marchetti C, Legnani C, Cavallari E, Castoldi E, Mascoli F, Ardissino D, Palareti G, Bernardi F. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol. 1997;17:2418-2422.
17. Kapur RK, Mills LA, Spitzer SG, Hultin MB. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol. 1997;17:2875-2879.
18. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost. 1997;78:1430-1433.
19. Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost. 1997;78:1426-1429.
20. Corral J, Gonzalez-Conjeiro R, Lozano ML, Rivera J, Heras I, Vicenie V. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol. 1997;99:304-307.
21. Watzke HH, Schüttrumpf J, Graf S, Huber K, Panzer S. Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. Thromb Res. 1997;87:521-526.
22. Arruda VR, Siquiera LH, Chiaparini LC, Coelho OR, Mansur AP, Ramires A, Annichino-Bizzacchi JM. Prevalence of the prothrombin gene variant 20210 G→A among patients with myocardial infarction. Cardiovasc Res. 1998;37:42-45.
23. Doggen CMJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors. Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation. 1998;97:1037-1041.
24. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, Servidei S, Tonali PA, Leone G. Prothrombin G20210A mutanl genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998;91:3562-3565.
25. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90: 1747-1750.
26. Longstreth WT, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, Raghunathan TE, Koepsell TD, Reitsma PH. Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A). Stroke. 1998;29:577-580.
27. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369:64-67.
28. März W, Seysewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet. 1995;344:526-527.
29. Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med. 1996;239:221-226.
30. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth Jr WT, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (Resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89:2817-2821.
31. van der Bom JG, Bots ML, Haverkate F, Slagboom E, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 1996;125:265-269.
32. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-919.
33. Demarmels Biasiutti F, Merlo C, Furlan M, Sulzer I, Binder BR, Lämmle B. No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis. 1995;6:456-459.
34. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
35. Doggen CJM, Manger Cats V, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost. 1998;80:281-285.
36. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction. Arg506 to Gln factor V mutation, and activated protein C resistance. Lancet. 1995;345: 321-322.